MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s12325-023-02496-z

Медицинская библиотека · Advances in therapy · 2023

Parents' Experience of Administering Vosoritide: A Daily Injectable for Children with Achondroplasia.

NiMhurchadha Sinead, Butler Karen, Argent Rob, Palm Katja, Baujat Genevieve, Cormier-Daire Valerie, Mohnike Klaus

СтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

INTRODUCTION

Vosoritide is the first approved pharmacological treatment for achondroplasia and is indicated for at-home injectable administration by a trained caregiver. This research aimed to explore parents' and children's experience of initiating vosoritide and administering this treatment at home.

METHODS

Qualitative telephone interviews were conducted with parents of children being treated with vosoritide in France and Germany. Interviews were transcribed and analysed using thematic analysis.

RESULTS

Fifteen parents participated in telephone interviews in September and October 2022. The median age of children in this sample was 8 years old (range 3-13 years) and children had been taking treatment from 6 weeks to 13 months. Four themes document families' experience with vosoritide: (1) awareness of vosoritide treatment, uncovering that parents first heard of vosoritide through their own research, patient advocacy groups, or through their physicians; (2) treatment understanding and decision-making, which found that their decision to take treatment is based on a desire to relieve future medical complications and increase height for improved independence, and they consider the extent to which the treatment has severe side effects; (3) training and initiation, which showed that the hospital initiation and training sessions varied considerably both across and within countries, with different treatment centres taking different approaches; and (4) managing treatment at home brings psychological and practical challenges, which are ultimately overcome with perseverance and available support.

CONCLUSIONS

Parents and children are resilient to challenges posed by a daily injectable treatment and highly motivated to improve their quality of life. Parents are prepared to overcome short-term treatment challenges for future gains in terms of health and functional independence for their children. Greater support could ensure they have the right information to initiate treatment and manage treatment at home, which will improve parents' and children's experience.

Для цитирования: NiMhurchadha Sinead, Butler Karen, Argent Rob, Palm Katja, Baujat Genevieve, Cormier-Daire Valerie, Mohnike Klaus. Parents' Experience of Administering Vosoritide: A Daily Injectable for Children with Achondroplasia.. Advances in therapy. 2023. DOI: 10.1007/s12325-023-02496-z.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.